Rogatko A, Schoeneck D, Jonas W, Tighiouart M, Khuri FR, Porter A. Translation of innovative designs into phase I trials. J Clin Oncol. 2007; 25(31):4982–6. https://doi.org/10.1200/JCO.2007.12.1012.
Article
PubMed
Google Scholar
Chiuzan C, Shtaynberger J, Manji GA, Duong JK, Schwartz GK, Ivanova A, Lee SM. Dose-finding designs for trials of molecularly targeted agents and immunotherapies. J Biopharm Stat. 2017; 27(3):477–94. https://doi.org/10.1080/10543406.2017.1289952. Publisher: Taylor & Francis.
Article
PubMed
PubMed Central
Google Scholar
Le Tourneau C, Lee JJ, Siu LL. Dose escalation methods in phase i cancer clinical trials. J Natl Cancer Inst. 2009; 101(10):708–20. https://doi.org/10.1093/jnci/djp079.
Article
CAS
PubMed
PubMed Central
Google Scholar
O’Quigley J, Pepe M, Fisher L. Continual reassessment method: A practical design for phase 1 clinical trials in cancer. Biometrics. 1990; 46(1):33–48. https://doi.org/10.2307/2531628.
Article
PubMed
Google Scholar
Tighiouart M, Rogatko A. Dose Finding with Escalation with Overdose Control (EWOC) in Cancer Clinical Trials. Stat Sci. 2010; 25(2):217–26. https://doi.org/10.1214/10-STS333.
Article
Google Scholar
O’Quigley J, Zohar S. Experimental designs for phase i and phase i/ii dose-finding studies. Br J Cancer. 2006; 94(5):609–13.
Article
PubMed
PubMed Central
Google Scholar
Iasonos A, Wilton AS, Riedel ER, Seshan VE, Spriggs DR. A comprehensive comparison of the continual reassessment method to the standard 3+ 3 dose escalation scheme in phase i dose-finding studies. Clin Trials. 2008; 5(5):465–77.
Article
PubMed
PubMed Central
Google Scholar
Wheeler GM, Mander AP, Bedding A, Brock K, Cornelius V, Grieve AP, Jaki T, Love SB, Weir CJ, Yap C, et al. How to design a dose-finding study using the continual reassessment method. BMC Med Res Methodol. 2019; 19(1):1–15.
Article
Google Scholar
Braun TM. The bivariate continual reassessment method: Extending the CRM to phase I trials of two competing outcomes. Control Clin Trials. 2002; 23(3):240–56. https://doi.org/10.1016/S0197-2456(01)00205-7.
Article
PubMed
Google Scholar
Zhang W, Sargent DJ, Mandrekar S. An adaptive dose-finding design incorporating both toxicity and efficacy. Stat Med. 2006; 25(14):2365–83. https://doi.org/10.1002/sim.2325.
Article
PubMed
Google Scholar
Ivanova A. A new dose-finding design for bivariate outcomes. Biometrics. 2003; 59(4):1001–7.
Article
PubMed
Google Scholar
Thall P, Cook J. Dose-Finding Based on Efficacy-Toxicity Trade-Offs. Biometrics. 2004; 60(3):684–93. https://doi.org/10.1111/j.0006-341X.2004.00218.x.
Article
PubMed
Google Scholar
Wages NA, Tait C. Seamless phase i/ii adaptive design for oncology trials of molecularly targeted agents. J Biopharm Stat. 2015; 25(5):903–20.
Article
PubMed
Google Scholar
Brock K, Billingham L, Copland M, Siddique S, Sirovica M, Yap C. Implementing the efftox dose-finding design in the matchpoint trial. BMC Med Res Methodol. 2017; 17(1):112.
Article
PubMed
PubMed Central
Google Scholar
Patnaik A, Kang SP, Rasco D, Papadopoulos KP, Elassaiss-Schaap J, Beeram M, Drengler R, Chen C, Smith L, Espino G, et al. Phase i study of pembrolizumab (mk-3475; anti–pd-1 monoclonal antibody) in patients with advanced solid tumors. Clin Cancer Res. 2015; 21(19):4286–93.
Article
CAS
PubMed
Google Scholar
Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, et al. Pembrolizumab for the treatment of non–small-cell lung cancer. New Engl J Med. 2015; 372(21):2018–28.
Article
PubMed
Google Scholar
Herbst RS, Baas P, Kim D-W, Felip E, Pérez-Gracia JL, Han J-Y, Molina J, Kim J-H, Arvis CD, Ahn M-J, et al. Pembrolizumab versus docetaxel for previously treated, pd-l1-positive, advanced non-small-cell lung cancer (keynote-010): a randomised controlled trial. Lancet. 2016; 387(10027):1540–50.
Article
CAS
PubMed
Google Scholar
Sharma S, de Vries EG, Infante JR, Oldenhuis CN, Gietema JA, Yang L, Bilic S, Parker K, Goldbrunner M, Scott JW, Burris HA. Safety, pharmacokinetics, and pharmacodynamics of the DR5 antibody LBY135 alone and in combination with capecitabine in patients with advanced solid tumors. Investig New Drugs. 2013; 32(1):135–44. https://doi.org/10.1007/s10637-013-9952-9.
Article
CAS
Google Scholar
Popovtzer A, Normolle D, Worden FP, Prince ME, Chepeha DB, Wolf GT, Bradford CR, Lawrence TS, Eisbruch A. Phase i trial of radiotherapy concurrent with twice-weekly gemcitabine for head and neck cancer: Translation from preclinical investigations aiming to improve the therapeutic ratio. Transl Oncol. 2014; 7(4):479–83. https://doi.org/10.1016/j.tranon.2014.04.016.
Article
PubMed
PubMed Central
Google Scholar
Kobayashi S, Nagano H, Sakai D, Eguchi H, Hatano E, Kanai M, Seo S, Taura K, Fujiwara Y, Ajiki T, Takemura S, Kubo S, Yanagimoto H, Toyokawa H, Tsuji A, Terajima H, Morita S, Ioka T. Phase i study of adjuvant gemcitabine or s-1 in patients with biliary tract cancers undergoing major hepatectomy: KHBO1003 study. Cancer Chemother Pharmacol. 2014; 74(4):699–709. https://doi.org/10.1007/s00280-014-2543-4.
Article
CAS
PubMed
Google Scholar
Khouri IF, Wei W, Korbling M, Turturro F, Ahmed S, Alousi A, Anderlini P, Ciurea S, Jabbour E, Oran B, Popat UR, Rondon G, Bassett RL, Gulbis A. BFR (bendamustine, fludarabine, and rituximab) allogeneic conditioning for chronic lymphocytic leukemia/lymphoma: reduced myelosuppression and GVHD. Blood. 2014; 124(14):2306–12. https://doi.org/10.1182/blood-2014-07-587519.
Article
CAS
PubMed
PubMed Central
Google Scholar
Ando Y, Inada-Inoue M, Mitsuma A, Yoshino T, Ohtsu A, Suenaga N, Sato M, Kakizume T, Robson M, Quadt C, Doi T. Phase i dose-escalation study of buparlisib (BKM120), an oral pan-class i PI3k inhibitor, in japanese patients with advanced solid tumors. Cancer Sci. 2014; 105(3):347–53. https://doi.org/10.1111/cas.12350.
Article
CAS
PubMed
PubMed Central
Google Scholar
Shaw AT, Kim D-W, Mehra R, Tan DSW, Felip E, Chow LQM, Camidge DR, Vansteenkiste J, Sharma S, Pas TD, Riely GJ, Solomon BJ, Wolf J, Thomas M, Schuler M, Liu G, Santoro A, Lau YY, Goldwasser M, Boral AL, Engelman JA. Ceritinib in ALK-rearranged non–small-cell lung cancer. New Engl J Med. 2014; 370(13):1189–97. https://doi.org/10.1056/nejmoa1311107.
Article
CAS
PubMed
Google Scholar
Saura C, Bendell J, Jerusalem G, Su S, Ru Q, Buck SD, Mills D, Ruquet S, Bosch A, Urruticoechea A, Beck JT, Tomaso ED, Sternberg DW, Massacesi C, Hirawat S, Dirix L, Baselga J. Phase ib study of buparlisib plus trastuzumab in patients with HER2-positive advanced or metastatic breast cancer that has progressed on trastuzumab-based therapy. Clin Cancer Res. 2014; 20(7):1935–45. https://doi.org/10.1158/1078-0432.ccr-13-1070.
Article
CAS
PubMed
Google Scholar
Rodon J, Tawbi HA, Thomas AL, Stoller RG, Turtschi CP, Baselga J, Sarantopoulos J, Mahalingam D, Shou Y, Moles MA, Yang L, Granvil C, Hurh E, Rose KL, Amakye DD, Dummer R, Mita AC. A phase i, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor sonidegib (LDE225) in patients with advanced solid tumors. Clin Cancer Res. 2014; 20(7):1900–9. https://doi.org/10.1158/1078-0432.ccr-13-1710.
Article
CAS
PubMed
Google Scholar
Faderl S, Balakrishnan K, Thomas DA, Ravandi F, Borthakur G, Burger J, Ferrajoli A, Cortes J, O’Brien S, Kadia T, Feliu J, Plunkett W, Gandhi V, Kantarjian HM. Phase i and extension study of clofarabine plus cyclophosphamide in patients with relapsed/refractory acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk. 2014; 14(3):231–8. https://doi.org/10.1016/j.clml.2013.12.001.
Article
PubMed
Google Scholar
Boulin M, Hillon P, Cercueil JP, Bonnetain F, Dabakuyo S, Minello A, Jouve JL, Lepage C, Bardou M, Wendremaire M, Guerard P, Denys A, Grandvuillemin A, Chauffert B, Bedenne L, Guiu B. Idarubicin-loaded beads for chemoembolisation of hepatocellular carcinoma: results of the IDASPHERE phase i trial. Aliment Pharmacol Ther. 2014; 39(11):1301–13. https://doi.org/10.1111/apt.12746.
Article
CAS
PubMed
Google Scholar
Rodon J, Braña I, Siu LL, Jonge MJD, Homji N, Mills D, Tomaso ED, Sarr C, Trandafir L, Massacesi C, Eskens F, Bendell JC. Phase i dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-class i PI3k inhibitor, in patients with advanced solid tumors. Investig New Drugs. 2014; 32(4):670–81. https://doi.org/10.1007/s10637-014-0082-9.
Article
CAS
Google Scholar
Doi T, Onozawa Y, Fuse N, Yoshino T, Yamazaki K, Watanabe J, Akimov M, Robson M, Boku N, Ohtsu A. Phase i dose-escalation study of the HSP90 inhibitor AUY922 in japanese patients with advanced solid tumors. Cancer Chemother Pharmacol. 2014; 74(3):629–36. https://doi.org/10.1007/s00280-014-2521-x.
Article
CAS
PubMed
PubMed Central
Google Scholar
Infante JR, Dees EC, Olszanski AJ, Dhuria SV, Sen S, Cameron S, Cohen RB. Phase i dose-escalation study of LCL161, an oral inhibitor of apoptosis proteins inhibitor, in patients with advanced solid tumors. J Clin Oncol. 2014; 32(28):3103–10. https://doi.org/10.1200/jco.2013.52.3993.
Article
CAS
PubMed
Google Scholar
Tsimberidou AM, Keating MJ, Jabbour EJ, Ravandi-Kashani F, O’Brien S, Estey E, Bekele N, Plunkett WK, Kantarjian H, Borthakur G. A phase i study of fludarabine, cytarabine, and oxaliplatin therapy in patients with relapsed or refractory acute myeloid leukemia. Clin Lymphoma Myeloma Leukemia. 2014; 14(5):395–4001. https://doi.org/10.1016/j.clml.2014.01.009.
Article
Google Scholar
Iyer SP, Beck JT, Stewart AK, Shah J, Kelly KR, Isaacs R, Bilic S, Sen S, Munshi NC. A phase IB multicentre dose-determination study of BHQ880 in combination with anti-myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal-related events. Br J Haematol. 2014; 167(3):366–75. https://doi.org/10.1111/bjh.13056.
Article
CAS
PubMed
Google Scholar
Brana I, Berger R, Golan T, Haluska P, Edenfield J, Fiorica J, Stephenson J, Martin LP, Westin S, Hanjani P, Jones MB, Almhanna K, Wenham RM, Sullivan DM, Dalton WS, Gunchenko A, Cheng JD, Siu LL, Gray JE. A parallel-arm phase i trial of the humanised anti-IGF-1r antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours. Br J Cancer. 2014; 111(10):1932–44. https://doi.org/10.1038/bjc.2014.497.
Article
CAS
PubMed
PubMed Central
Google Scholar
Isakoff SJ, Wang D, Campone M, Calles A, Leip E, Turnbull K, Bardy-Bouxin N, Duvillié L, Calvo E. Bosutinib plus capecitabine for selected advanced solid tumours: results of a phase 1 dose-escalation study. Br J Cancer. 2014; 111(11):2058–66. https://doi.org/10.1038/bjc.2014.508.
Article
CAS
PubMed
PubMed Central
Google Scholar
Brennan RC, Furman W, Mao S, Wu J, Turner DC, Stewart CF, Santana V, McGregor LM. Phase i dose escalation and pharmacokinetic study of oral gefitinib and irinotecan in children with refractory solid tumors. Cancer Chemother Pharmacol. 2014; 74(6):1191–8. https://doi.org/10.1007/s00280-014-2593-7.
Article
CAS
PubMed
PubMed Central
Google Scholar
Gandhi L, Bahleda R, Tolaney SM, Kwak EL, Cleary JM, Pandya SS, Hollebecque A, Abbas R, Ananthakrishnan R, Berkenblit A, Krygowski M, Liang Y, Turnbull KW, Shapiro GI, Soria J-C. Phase i study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2–dependent and other solid tumors. J Clin Oncol. 2014; 32(2):68–75. https://doi.org/10.1200/jco.2012.47.2787.
Article
CAS
PubMed
Google Scholar
Fanale M, Assouline S, Kuruvilla J, Solal-Céligny P, Heo DS, Verhoef G, Corradini P, Abramson JS, Offner F, Engert A, Dyer MJS, Carreon D, Ewald B, Baeck J, Younes A, Freedman AS. Phase IA/II, multicentre, open-label study of the CD40 antagonistic monoclonal antibody lucatumumab in adult patients with advanced non-hodgkin or hodgkin lymphoma. Br J Haematol. 2013; 164(2):258–65. https://doi.org/10.1111/bjh.12630.
Article
PubMed
PubMed Central
CAS
Google Scholar
Das P, Eng C, Rodriguez-Bigas MA, Chang GJ, Skibber JM, You YN, Maru DM, Munsell MF, Clemons MV, Kopetz SE, Garrett CR, Shureiqi I, Delclos ME, Krishnan S, Crane CH. Preoperative radiation therapy with concurrent capecitabine, bevacizumab, and erlotinib for rectal cancer: A phase 1 trial. Int J Radiat Oncol Biol Phys. 2014; 88(2):301–5. https://doi.org/10.1016/j.ijrobp.2013.10.034.
Article
CAS
PubMed
Google Scholar
Besse B, Heist RS, Papadmitrakopoulou VA, Camidge DR, Beck JT, Schmid P, Mulatero C, Miller N, Dimitrijevic S, Urva S, Pylvaenaeinen I, Petrovic K, Johnson BE. A phase ib dose-escalation study of everolimus combined with cisplatin and etoposide as first-line therapy in patients with extensive-stage small-cell lung cancer. Ann Oncol. 2014; 25(2):505–11. https://doi.org/10.1093/annonc/mdt535.
Article
CAS
PubMed
Google Scholar
Cruz CRY, Micklethwaite KP, Savoldo B, Ramos CA, Lam S, Ku S, Diouf O, Liu E, Barrett AJ, Ito S, Shpall EJ, Krance RA, Kamble RT, Carrum G, Hosing CM, Gee AP, Mei Z, Grilley BJ, Heslop HE, Rooney CM, Brenner MK, Bollard CM, Dotti G. Infusion of donor-derived CD19-redirected virus-specific t cells for b-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood. 2013; 122(17):2965–73. https://doi.org/10.1182/blood-2013-06-506741.
Article
CAS
PubMed
PubMed Central
Google Scholar
Thornton KA, Chen AR, Trucco MM, Shah P, Wilky BA, Gul N, Carrera-Haro MA, Ferreira MF, Shafique U, Powell JD, Meyer CF, Loeb DM. A dose-finding study of temsirolimus and liposomal doxorubicin for patients with recurrent and refractory bone and soft tissue sarcoma. Int J Cancer. 2013; 133(4):997–1005. https://doi.org/10.1002/ijc.28083.
Article
CAS
PubMed
Google Scholar
Sharma S, Beck J, Mita M, Paul S, Woo MM, Squier M, Gadbaw B, Prince HM. A phase i dose-escalation study of intravenous panobinostat in patients with lymphoma and solid tumors. Investig New Drugs. 2013; 31(4):974–85. https://doi.org/10.1007/s10637-013-9930-2.
Article
CAS
Google Scholar
Sessa C, Shapiro GI, Bhalla KN, Britten C, Jacks KS, Mita M, Papadimitrakopoulou V, Pluard T, Samuel TA, Akimov M, Quadt C, Fernandez-Ibarra C, Lu H, Bailey S, Chica S, Banerji U. First-in-human phase i dose-escalation study of the HSP90 inhibitor AUY922 in patients with advanced solid tumors. Clin Cancer Res. 2013; 19(13):3671–80. https://doi.org/10.1158/1078-0432.ccr-12-3404.
Article
CAS
PubMed
Google Scholar
Schott AF, Landis MD, Dontu G, Griffith KA, Layman RM, Krop I, Paskett LA, Wong H, Dobrolecki LE, Lewis MT, Froehlich AM, Paranilam J, Hayes DF, Wicha MS, Chang JC. Preclinical and clinical studies of gamma secretase inhibitors with docetaxel on human breast tumors. Clin Cancer Res. 2013; 19(6):1512–24. https://doi.org/10.1158/1078-0432.ccr-11-3326.
Article
CAS
PubMed
PubMed Central
Google Scholar
Mangiacavalli S, Pochintesta L, Pascutto C, Cocito F, Cazzola M, Corso A. Good clinical activity and favorable toxicity profile of once weekly bortezomib, fotemustine, and dexamethasone (b-MuD) for the treatment of relapsed multiple myeloma. Am J Hematol. 2012; 88(2):102–6. https://doi.org/10.1002/ajh.23358.
Article
PubMed
PubMed Central
CAS
Google Scholar
Larocca A, Montefusco V, Bringhen S, Rossi D, Crippa C, Mina R, Galli M, Marcatti M, Verde GL, Giuliani N, Magarotto V, Guglielmelli T, Rota-Scalabrini D, Omedé P, Santagostino A, Baldi I, Carella AM, Boccadoro M, Corradini P, Palumbo A. Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study. Blood. 2013; 122(16):2799–806. https://doi.org/10.1182/blood-2013-03-488676.
Article
CAS
PubMed
Google Scholar
Harvey RD, Owonikoko TK, Lewis CM, Akintayo A, Chen Z, Tighiouart M, Ramalingam SS, Fanucchi MP, Nadella P, Rogatko A, Shin DM, El-Rayes B, Khuri FR, Kauh JS. A phase 1 bayesian dose selection study of bortezomib and sunitinib in patients with refractory solid tumor malignancies. Br J Cancer. 2013; 108(4):762–5. https://doi.org/10.1038/bjc.2012.604.
Article
CAS
PubMed
PubMed Central
Google Scholar
Finn RS, Poon RTP, Yau T, Klümpen H-J, Chen L-T, Kang Y-K, Kim T-Y, Gomez-Martin C, Rodriguez-Lope C, Kunz T, Paquet T, Brandt U, Sellami D, Bruix J. Phase i study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma. J Hepatol. 2013; 59(6):1271–7. https://doi.org/10.1016/j.jhep.2013.07.029.
Article
CAS
PubMed
Google Scholar
DeAngelo DJ, Spencer A, Bhalla KN, Prince HM, Fischer T, Kindler T, Giles FJ, Scott JW, Parker K, Liu A, Woo M, Atadja P, Mishra KK, Ottmann OG. Phase ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies. Leukemia. 2013; 27(8):1628–36. https://doi.org/10.1038/leu.2013.38.
Article
CAS
PubMed
Google Scholar
Chiappella A, Tucci A, Castellino A, Pavone V, Baldi I, Carella AM, Orsucci L, Zanni M, Salvi F, Liberati AM, Gaidano G, Bottelli C, Rossini B, Perticone S, Masi PD, Ladetto M, Ciccone G, Palumbo A, Rossi G, and UV. Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large b-cell lymphoma: a phase i study by the fondazione italiana linfomi. Haematologica. 2013; 98(11):1732–8. https://doi.org/10.3324/haematol.2013.085134.
Article
CAS
PubMed
PubMed Central
Google Scholar
Cannon DM, Mehta MP, Adkison JB, Khuntia D, Traynor AM, Tomé WA, Chappell RJ, Tolakanahalli R, Mohindra P, Bentzen SM, Cannon GM. Dose-limiting toxicity after hypofractionated dose-escalated radiotherapy in non–small-cell lung cancer. J Clin Oncol. 2013; 31(34):4343–8. https://doi.org/10.1200/jco.2013.51.5353.
Article
PubMed
PubMed Central
Google Scholar
Angevin E, Lopez-Martin JA, Lin C-C, Gschwend JE, Harzstark A, Castellano D, Soria J-C, Sen P, Chang J, Shi M, Kay A, Escudier B. Phase i study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma. Clin Cancer Res. 2013; 19(5):1257–68. https://doi.org/10.1158/1078-0432.ccr-12-2885.
Article
CAS
PubMed
Google Scholar
Foster MC, Amin C, Voorhees PM, van Deventer HW, Richards KL, Ivanova A, Whitman J, Chiu WM, Barr ND, Shea T. A phase i dose-escalation study of clofarabine in combination with fractionated gemtuzumab ozogamicin in patients with refractory or relapsed acute myeloid leukemia. Leuk Lymphoma. 2012; 53(7):1331–7. https://doi.org/10.3109/10428194.2011.647313.
Article
CAS
PubMed
Google Scholar
Tsien CI, Brown D, Normolle D, Schipper M, Piert M, Junck L, Heth J, Gomez-Hassan D, Haken RKT, Chenevert T, Cao Y, Lawrence T. Concurrent temozolomide and dose-escalated intensity-modulated radiation therapy in newly diagnosed glioblastoma. Clin Cancer Res. 2011; 18(1):273–9. https://doi.org/10.1158/1078-0432.ccr-11-2073.
Article
PubMed
PubMed Central
Google Scholar
Tevaarwerk A, Wilding G, Eickhoff J, Chappell R, Sidor C, Arnott J, Bailey H, Schelman W, Liu G. Phase i study of continuous MKC-1 in patients with advanced or metastatic solid malignancies using the modified time-to-event continual reassessment method (TITE-CRM) dose escalation design. Investig New Drugs. 2011; 30(3):1039–45. https://doi.org/10.1007/s10637-010-9629-6.
Article
CAS
Google Scholar
Sinha R, Kaufman JL, Khoury HJ, King N, Shenoy PJ, Lewis C, Bumpers K, Hutchison-Rzepka A, Tighiouart M, Heffner LT, Lechowicz MJ, Lonial S, Flowers CR. A phase 1 dose escalation study of bortezomib combined with rituximab, cyclophosphamide, doxorubicin, modified vincristine, and prednisone for untreated follicular lymphoma and other low-grade b-cell lymphomas. Cancer. 2012; 118(14):3538–48. https://doi.org/10.1002/cncr.26660.
Article
CAS
PubMed
Google Scholar
Schneider BJ, Kalemkerian GP, Bradley D, Smith DC, Egorin MJ, Daignault S, Dunn R, Hussain M. Phase i study of vorinostat (suberoylanilide hydroxamic acid, NSC 701852) in combination with docetaxel in patients with advanced and relapsed solid malignancies. Investig New Drugs. 2010; 30(1):249–57. https://doi.org/10.1007/s10637-010-9503-6.
Article
CAS
Google Scholar
Roberts AW, Seymour JF, Brown JR, Wierda WG, Kipps TJ, Khaw SL, Carney DA, He SZ, Huang DCS, Xiong H, Cui Y, Busman TA, McKeegan EM, Krivoshik AP, Enschede SH, Humerickhouse R. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: Results of a phase i study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol. 2012; 30(5):488–96. https://doi.org/10.1200/jco.2011.34.7898.
Article
CAS
PubMed
Google Scholar
Reardon DA, Vredenburgh JJ, Desjardins A, Peters KB, Sathornsumetee S, Threatt S, Sampson JH, Herndon JE, Coan A, McSherry F, Rich JN, McLendon RE, Zhang S, Friedman HS. Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma. J Neuro-Oncol. 2012; 108(3):499–506. https://doi.org/10.1007/s11060-012-0848-x.
Article
CAS
Google Scholar
Moulder S, Gladish G, Ensor J, Gonzalez-Angulo AM, Cristofanilli M, Murray JL, Booser D, Giordano SH, Brewster A, Moore J, Rivera E, Hortobagyi GN, Tran HT. A phase 1 study of weekly everolimus (RAD001) in combination with docetaxel in patients with metastatic breast cancer. Cancer. 2011; 118(9):2378–84. https://doi.org/10.1002/cncr.26571.
Article
PubMed
CAS
Google Scholar
Mazard T, Ychou M, Thezenas S, Poujol S, Pinguet F, Thirion A, Bleuse JP, Portales F, Samalin E, Assenat E. Feasibility of biweekly combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in patients with metastatic solid tumors: results of a two-step phase i trial: XELIRI and XELIRINOX. Cancer Chemother Pharmacol. 2011; 69(3):807–14. https://doi.org/10.1007/s00280-011-1764-z.
Article
PubMed
CAS
Google Scholar
Markman B, Tabernero J, Krop I, Shapiro GI, Siu L, Chen LC, Mita M, Cuero MM, Stutvoet S, Birle D, Anak O, Hackl W, Baselga J. Phase i safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors. Ann Oncol. 2012; 23(9):2399–408. https://doi.org/10.1093/annonc/mds011.
Article
CAS
PubMed
Google Scholar
Lu C, Stewart DJ, Lee JJ, Ji L, Ramesh R, Jayachandran G, Nunez MI, Wistuba II, Erasmus JJ, Hicks ME, Grimm EA, Reuben JM, Baladandayuthapani V, Templeton NS, McMannis JD, Roth JA. Phase i clinical trial of systemically administered TUSC2(FUS1)-nanoparticles mediating functional gene transfer in humans. PLoS ONE. 2012; 7(4):34833. https://doi.org/10.1371/journal.pone.0034833.
Article
CAS
Google Scholar
Kawahara M, Kubo A, Komuta K, Fujita Y, Sasaki Y, Fukushima M, Daimon T, Furuse K, Mishima M, Mio T. A phase i study of amrubicin and fixed dose of irinotecan (CPT-11) in relapsed small cell lung cancer: Japan multinational trial organization LC0303. J Thorac Oncol. 2012; 7(12):1845–9. https://doi.org/10.1097/jto.0b013e3181e47a62.
Article
CAS
PubMed
Google Scholar
Jones DR, Moskaluk CA, Gillenwater HH, Petroni GR, Burks SG, Philips J, Rehm PK, Olazagasti J, Kozower BD, Bao Y. Phase i trial of induction histone deacetylase and proteasome inhibition followed by surgery in non–small-cell lung cancer. J Thor Oncol. 2012; 7(11):1683–90. https://doi.org/10.1097/jto.0b013e318267928d.
Article
CAS
Google Scholar
Jakubowiak AJ, Dytfeld D, Griffith KA, Lebovic D, Vesole DH, Jagannath S, Al-Zoubi A, Anderson T, Nordgren B, Detweiler-Short K, Stockerl-Goldstein K, Ahmed A, Jobkar T, Durecki DE, McDonnell K, Mietzel M, Couriel D, Kaminski M, Vij R. A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood. 2012; 120(9):1801–9. https://doi.org/10.1182/blood-2012-04-422683.
Article
CAS
PubMed
PubMed Central
Google Scholar
Geletneky K, Huesing J, Rommelaere J, Schlehofer JR, Leuchs B, Dahm M, Krebs O, von Knebel Doeberitz M, Huber B, Hajda J. Phase i/IIa study of intratumoral/intracerebral or intravenous/intracerebral administration of parvovirus h-1 (ParvOryx) in patients with progressive primary or recurrent glioblastoma multiforme: ParvOryx01 protocol. BMC Cancer. 2012; 12(1). https://doi.org/10.1186/1471-2407-12-99.
Feng M, Smith DE, Normolle DP, Knol JA, Pan CC, Ben-Josef E, Lu Z, Feng MR, Chen J, Ensminger W, Lawrence TS. A phase i clinical and pharmacology study using amifostine as a radioprotector in dose-escalated whole liver radiation therapy. Int J Radiat Oncol Biol Phys. 2012; 83(5):1441–7. https://doi.org/10.1016/j.ijrobp.2011.10.020.
Article
CAS
PubMed
PubMed Central
Google Scholar
Farid M, Chowbay B, Chen X, Tan SH, Ramasamy S, Koo WH, Toh HC, Choo SP, Ong SYK. Phase i pharmacokinetic study of chronomodulated dose-intensified combination of capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer. Cancer Chemother Pharmacol. 2012; 70(1):141–50. https://doi.org/10.1007/s00280-012-1895-x.
Article
CAS
PubMed
Google Scholar
Crew KD, Brown P, Greenlee H, Bevers TB, Arun B, Hudis C, McArthur HL, Chang J, Rimawi M, Vornik L, Cornelison TL, Wang A, Hibshoosh H, Ahmed A, Terry MB, Santella RM, Lippman SM, Hershman DL. Phase IB randomized, double-blinded, placebo-controlled, dose escalation study of polyphenon e in women with hormone receptor-negative breast cancer. Cancer Prev Res. 2012; 5(9):1144–54. https://doi.org/10.1158/1940-6207.capr-12-0117.
Article
CAS
Google Scholar
Bendell JC, Rodon J, Burris HA, de Jonge M, Verweij J, Birle D, Demanse D, Buck SSD, Ru QC, Peters M, Goldbrunner M, Baselga J. Phase i, dose-escalation study of BKM120, an oral pan-class i PI3k inhibitor, in patients with advanced solid tumors. J Clin Oncol. 2012; 30(3):282–90. https://doi.org/10.1200/jco.2011.36.1360.
Article
CAS
PubMed
Google Scholar
Ben-Josef E, Schipper M, Francis IR, Hadley S, Ten-Haken R, Lawrence T, Normolle D, Simeone DM, Sonnenday C, Abrams R, Leslie W, Khan G, Zalupski MM. A phase i/II trial of intensity modulated radiation (IMRT) dose escalation with concurrent fixed-dose rate gemcitabine (FDR-g) in patients with unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys. 2012; 84(5):1166–71. https://doi.org/10.1016/j.ijrobp.2012.02.051.
Article
PubMed
PubMed Central
Google Scholar
Stasi AD, Tey S-K, Dotti G, Fujita Y, Kennedy-Nasser A, Martinez C, Straathof K, Liu E, Durett AG, Grilley B, Liu H, Cruz CR, Savoldo B, Gee AP, Schindler J, Krance RA, Heslop HE, Spencer DM, Rooney CM, Brenner MK. Inducible apoptosis as a safety switch for adoptive cell therapy. New Engl J Med. 2011; 365(18):1673–83. https://doi.org/10.1056/nejmoa1106152.
Article
PubMed
Google Scholar
Warren KE, Goldman S, Pollack IF, Fangusaro J, Schaiquevich P, Stewart CF, Wallace D, Blaney SM, Packer R, MacDonald T, Jakacki R, Boyett JM, Kun LE. Phase i trial of lenalidomide in pediatric patients with recurrent, refractory, or progressive primary CNS tumors: Pediatric brain tumor consortium study PBTC-018. J Clin Oncol. 2011; 29(3):324–9. https://doi.org/10.1200/jco.2010.31.3601.
Article
CAS
PubMed
Google Scholar
Vansteenkiste J, Solomon B, Boyer M, Wolf J, Miller N, Scala LD, Pylvaenaeinen I, Petrovic K, Dimitrijevic S, Anrys B, Laack E. Everolimus in combination with pemetrexed in patients with advanced non-small cell lung cancer previously treated with chemotherapy: A phase i study using a novel, adaptive bayesian dose-escalation model. J Thor Oncol. 2011; 6(12):2120–9. https://doi.org/10.1097/jto.0b013e3182307ede.
Article
Google Scholar
Terakura S, Atsuta Y, Sawa M, Ohashi H, Kato T, Nishiwaki S, Imahashi N, Yasuda T, Murata M, Miyamura K, Suzuki R, Naoe T, Ito T, Morishita Y. A prospective dose-finding trial using a modified continual reassessment method for optimization of fludarabine plus melphalan conditioning for marrow transplantation from unrelated donors in patients with hematopoietic malignancies. Annals Oncol. 2011; 22(8):1865–71. https://doi.org/10.1093/annonc/mdq673.
Article
CAS
Google Scholar
Smith BD, Jones RJ, Cho E, Kowalski J, Karp JE, Gore SD, Vala M, Meade B, Baker SD, Zhao M, Piantadosi S, Zhang Z, Blumenthal G, Warlick ED, Brodsky RA, Murgo A, Rudek MA, Matsui WH. Differentiation therapy in poor risk myeloid malignancies: Results of a dose finding study of the combination bryostatin-1 and GM-CSF. Leuk Res. 2011; 35(1):87–94. https://doi.org/10.1016/j.leukres.2010.06.001.
Article
CAS
PubMed
Google Scholar
Satoh T, Ura T, Yamada Y, Yamazaki K, Tsujinaka T, Munakata M, Nishina T, Okamura S, Esaki T, Sasaki Y, Koizumi W, Kakeji Y, Ishizuka N, Hyodo I, Sakata Y. Genotype-directed, dose-finding study of irinotecan in cancer patients with UGT1a1*28 and/or UGT1a1*6 polymorphisms. Cancer Sci. 2011; 102(10):1868–73. https://doi.org/10.1111/j.1349-7006.2011.02030.x.
Article
CAS
PubMed
Google Scholar
Mehnert JM, Tan AR, Moss R, Poplin E, Stein MN, Sovak M, Levinson K, Lin H, Kane M, Gounder M, Lin Y, Shih WJ, White E, Rubin EH, Karantza V. Rationally designed treatment for solid tumors with MAPK pathway activation: A phase i study of paclitaxel and bortezomib using an adaptive dose-finding approach. Mol Cancer Ther. 2011; 10(8):1509–19. https://doi.org/10.1158/1535-7163.mct-10-0944.
Article
CAS
PubMed
PubMed Central
Google Scholar
Magenau J, Tobai H, Pawarode A, Braun T, Peres E, Reddy P, Kitko C, Choi S, Yanik G, Frame D, Harris A, Erba H, Kujawski L, Elenitoba-Johnson K, Sanks J, Jones D, Paczesny S, Ferrara J, Levine J, Mineishi S. Clofarabine and busulfan conditioning facilitates engraftment and provides significant antitumor activity in nonremission hematologic malignancies. Blood. 2011; 118(15):4258–64. https://doi.org/10.1182/blood-2011-06-358010.
Article
CAS
PubMed
Google Scholar
Koolen SLW, Witteveen PO, Jansen RS, Langenberg MHG, Kronemeijer RH, Nol A, Garcia-Ribas I, Callies S, Benhadji KA, Slapak CA, Beijnen JH, Voest EE, Schellens JHM. Phase i study of oral gemcitabine prodrug (LY2334737) alone and in combination with erlotinib in patients with advanced solid tumors. Clin Cancer Res. 2011; 17(18):6071–82. https://doi.org/10.1158/1078-0432.ccr-11-0353.
Article
CAS
PubMed
Google Scholar
Kim KB, Chesney J, Robinson D, Gardner H, Shi MM, Kirkwood JM. Phase i/II and pharmacodynamic study of dovitinib (TKI258), an inhibitor of fibroblast growth factor receptors and VEGF receptors, in patients with advanced melanoma. Clin Cancer Res. 2011; 17(23):7451–61. https://doi.org/10.1158/1078-0432.ccr-11-1747.
Article
CAS
PubMed
Google Scholar
Jerusalem G, Fasolo A, Dieras V, Cardoso F, Bergh J, Vittori L, Zhang Y, Massacesi C, Sahmoud T, Gianni L. Phase i trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer. Breast Cancer Res Treat. 2010; 125(2):447–55. https://doi.org/10.1007/s10549-010-1260-x.
Article
PubMed
CAS
Google Scholar
Jakubowiak AJ, Griffith KA, Reece DE, Hofmeister CC, Lonial S, Zimmerman TM, Campagnaro EL, Schlossman RL, Laubach JP, Raje NS, Anderson T, Mietzel MA, Harvey CK, Wear SM, Barrickman JC, Tendler CL, Esseltine D-L, Kelley SL, Kaminski MS, Anderson KC, Richardson PG. Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 multiple myeloma research consortium trial. Blood. 2011; 118(3):535–43. https://doi.org/10.1182/blood-2011-02-334755.
Article
CAS
PubMed
PubMed Central
Google Scholar
Geoerger B, Hargrave D, Thomas F, Ndiaye A, Frappaz D, Andreiuolo F, Varlet P, Aerts I, Riccardi R, Jaspan T, Chatelut E, Deley M-CL, Paoletti X, Saint-Rose C, Leblond P, Morland B, Gentet J-C, Meresse V, and GV. Innovative therapies for children with cancer pediatric phase i study of erlotinib in brainstem glioma and relapsing/refractory brain tumors. Neuro-Oncology. 2010; 13(1):109–18. https://doi.org/10.1093/neuonc/noq141.
Article
PubMed
PubMed Central
CAS
Google Scholar
Gandhi L, Camidge DR, de Oliveira MR, Bonomi P, Gandara D, Khaira D, Hann CL, McKeegan EM, Litvinovich E, Hemken PM, Dive C, Enschede SH, Nolan C, Chiu Y-L, Busman T, Xiong H, Krivoshik AP, Humerickhouse R, Shapiro GI, Rudin CM. Phase i study of navitoclax (ABT-263), a novel bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J Clin Oncol. 2011; 29(7):909–16. https://doi.org/10.1200/jco.2010.31.6208.
Article
CAS
PubMed
PubMed Central
Google Scholar
Fouladi M, Stewart CF, Olson J, Wagner LM, Onar-Thomas A, Kocak M, Packer RJ, Goldman S, Gururangan S, Gajjar A, Demuth T, Kun LE, Boyett JM, Gilbertson RJ. Phase i trial of MK-0752 in children with refractory CNS malignancies: A pediatric brain tumor consortium study. J Clin Oncol. 2011; 29(26):3529–34. https://doi.org/10.1200/jco.2011.35.7806.
Article
CAS
PubMed
PubMed Central
Google Scholar
Rathkopf D, Wong BY, Ross RW, Anand A, Tanaka E, Woo MM, Hu J, Dzik-Jurasz A, Yang W, Scher HI. A phase i study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer. Cancer Chemother Pharmacol. 2010; 66(1):181–9. https://doi.org/10.1007/s00280-010-1289-x.
Article
CAS
PubMed
Google Scholar
Peereboom DM, Supko JG, Carson KA, Batchelor T, Phuphanich S, Lesser G, Mikkelson T, Fisher J, Desideri S, He X, Grossman SA. A phase i/II trial and pharmacokinetic study of ixabepilone in adult patients with recurrent high-grade gliomas. J Neuro-Oncol. 2010; 100(2):261–8. https://doi.org/10.1007/s11060-010-0190-0.
Article
CAS
Google Scholar
O’Donnell PH, Artz AS, Undevia SD, Pai RK, Cerro PD, Horowitz S, Godley LA, Hart J, Innocenti F, Larson RA, Odenike OM, Stock W, Besien KV. Phase i study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive disease. Leuk Lymphoma. 2010; 51(12):2240–9. https://doi.org/10.3109/10428194.2010.520773.
Article
PubMed
PubMed Central
CAS
Google Scholar
Furman RR, Martin P, Ruan J, Cheung Y-KK, Vose JM, LaCasce AS, Elstrom R, Coleman M, Leonard JP. Phase 1 trial of bortezomib plus r-CHOP in previously untreated patients with aggressive non-hodgkin lymphoma. Cancer. 2010; 116(23):5432–9. https://doi.org/10.1002/cncr.25509.
Article
CAS
PubMed
Google Scholar
Fouladi M, Stewart CF, Blaney SM, Onar-Thomas A, Schaiquevich P, Packer RJ, Gajjar A, Kun LE, Boyett JM, Gilbertson RJ. Phase i trial of lapatinib in children with refractory CNS malignancies: A pediatric brain tumor consortium study. J Clin Oncol. 2010; 28(27):4221–7. https://doi.org/10.1200/jco.2010.28.4687.
Article
CAS
PubMed
PubMed Central
Google Scholar
Andre F, Campone M, O’Regan R, Manlius C, Massacesi C, Tarek S, Mukhopadhyay P, Soria J-C, Naughton M, Hurvitz SA. Phase i study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab. J Clin Oncol. 2010; 28(34):5110–5. https://doi.org/10.1200/jco.2009.27.8549.
Article
CAS
PubMed
Google Scholar
Loeb DM, Garrett-Mayer E, Hobbs RF, Prideaux AR, Sgouros G, Shokek O, Wharam MD, Scott T, Schwartz CL. Dose-finding study of153sm-EDTMP in patients with poor-prognosis osteosarcoma. Cancer. 2009; 115(11):2514–22. https://doi.org/10.1002/cncr.24286.
Article
CAS
PubMed
Google Scholar
Li B. -s., Zhou T, Wang Z. -t., Li H. -s., Sun H. -f., Zhang Z. -c., Lin H. -q., Wei Y. -m., Gong H. -y., Huang W, Yi Y, Wang L. -y.Phase i study of concurrent selective lymph node late course accelerated hyper-fractionated radiotherapy and capecitabine, cisplatin for locally advanced esophageal squamous cell carcinoma. Radiother Oncol. 2009; 93(3):458–61. https://doi.org/10.1016/j.radonc.2009.08.002.
Article
PubMed
Google Scholar
Demetri GD, Russo PL, MacPherson IRJ, Wang D, Morgan JA, Brunton VG, Paliwal P, Agrawal S, Voi M, Evans TRJ. Phase i dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors. Clin Cancer Res. 2009; 15(19):6232–40. https://doi.org/10.1158/1078-0432.ccr-09-0224.
Article
CAS
PubMed
Google Scholar
Borghaei H, Alpaugh K, Hedlund G, Forsberg G, Langer C, Rogatko A, Hawkins R, Dueland S, Lassen U, Cohen RB. Phase i dose escalation, pharmacokinetic and pharmacodynamic study of naptumomab estafenatox alone in patients with advanced cancer and with docetaxel in patients with advanced non–small-cell lung cancer. J Clin Oncol. 2009; 27(25):4116–23. https://doi.org/10.1200/jco.2008.20.2515.
Article
CAS
PubMed
PubMed Central
Google Scholar
Bailey DB, Rassnick KM, Dykes NL, Pendyala L. Phase i evaluation of carboplatin by use of a dosing strategy based on a targeted area under the platinum concentration-versus-time curve and individual glomerular filtration rate in cats with tumors. Am J Vet Res. 2009; 70(6):770–6. https://doi.org/10.2460/ajvr.70.6.770.
Article
CAS
PubMed
Google Scholar
Trümper L, Zwick C, Ziepert M, Hohloch K, Schmits R, Mohren M, Liersch R, Bentz M, Graeven U, Wruck U, Hoffmann M, Metzner B, Hasenclever D, Loeffler M, Pfreundschuh M. Dose-escalated CHOEP for the treatment of young patients with aggressive non-hodgkin’s lymphoma: I. a randomized dose escalation and feasibility study with bi- and tri-weekly regimens. Ann Oncol. 2008; 19(3):538–44. https://doi.org/10.1093/annonc/mdm497.
Article
PubMed
Google Scholar
Saji S, Toi M, Morita S, Iwata H, Ito Y, Ohno S, Kobayashi T, Hozumi Y, Sakamoto J. Dose-finding phase i and pharmacokinetic study of capecitabine (xeloda) in combination with epirubicin and cyclophosphamide (CEX) in patients with inoperable or metastatic breast cancer. Oncology. 2007; 72(5-6):330–7. https://doi.org/10.1159/000113062.
Article
CAS
PubMed
Google Scholar
Rao S, Starling N, Cunningham D, Benson M, Wotherspoon A, Lüpfert C, Kurek R, Oates J, Baselga J, Hill A. Phase i study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer. Br J Cancer. 2008; 99(6):868–74. https://doi.org/10.1038/sj.bjc.6604622.
Article
CAS
PubMed
PubMed Central
Google Scholar
Neuenschwander B, Branson M, Gsponer T. Critical aspects of the bayesian approach to phase i cancer trials. Stat Med. 2008; 27(13):2420–39. https://doi.org/10.1002/sim.3230.
Article
PubMed
Google Scholar
MacDonald TJ, Stewart CF, Kocak M, Goldman S, Ellenbogen RG, Phillips P, Lafond D, Poussaint TY, Kieran MW, Boyett JM, Kun LE. Phase i clinical trial of cilengitide in children with refractory brain tumors: Pediatric brain tumor consortium study PBTC-012. J Clin Oncol. 2008; 26(6):919–24. https://doi.org/10.1200/jco.2007.14.1812.
Article
CAS
PubMed
Google Scholar
Jimeno A, Rudek MA, Kulesza P, Ma WW, Wheelhouse J, Howard A, Khan Y, Zhao M, Jacene H, Messersmith WA, Laheru D, Donehower RC, Garrett-Mayer E, Baker SD, Hidalgo M. Pharmacodynamic-guided modified continuous reassessment method–based, dose-finding study of rapamycin in adult patients with solid tumors. J Clin Oncol. 2008; 26(25):4172–9. https://doi.org/10.1200/jco.2008.16.2347.
Article
CAS
PubMed
PubMed Central
Google Scholar
Gururangan S, Turner CD, Stewart CF, O’Shaughnessy M, Kocak M, Poussaint TY, Phillips PC, Goldman S, Packer R, Pollack IF, Blaney SM, Karsten V, Gerson SL, Boyett JM, Friedman HS, Kun LE. Phase i trial of VNP40101m (cloretazine) in children with recurrent brain tumors: A pediatric brain tumor consortium study. Clin Cancer Res. 2008; 14(4):1124–30. https://doi.org/10.1158/1078-0432.ccr-07-4242.
Article
CAS
PubMed
Google Scholar
Guillot B, Khamari A, Cupissol D, Delaunay M, Bedane C, Dreno B, Picot MC, Dereure O. Temozolomide associated with PEG-interferon in patients with metastatic melanoma: a multicenter prospective phase i/II study. Melanoma Res. 2008; 18(2):141–6. https://doi.org/10.1097/cmr.0b013e3282f6309c.
Article
CAS
PubMed
Google Scholar
Grossman SA, Carson KA, Phuphanich S, Batchelor T, Peereboom D, Nabors LB, Lesser G, Hausheer F, Supko JG. Phase i and pharmacokinetic study of karenitecin in patients with recurrent malignant gliomas. Neuro-Oncology. 2008; 10(4):608–16. https://doi.org/10.1215/15228517-2008-030.
Article
CAS
PubMed
PubMed Central
Google Scholar
de Bono JS, Kristeleit R, Tolcher A, Fong P, Pacey S, Karavasilis V, Mita M, Shaw H, Workman P, Kaye S, Rowinsky EK, Aherne W, Atadja P, Scott JW, Patnaik A. Phase i pharmacokinetic and pharmacodynamic study of LAQ824, a hydroxamate histone deacetylase inhibitor with a heat shock protein-90 inhibitory profile, in patients with advanced solid tumors. Clin Cancer Res. 2008; 14(20):6663–73. https://doi.org/10.1158/1078-0432.ccr-08-0376.
Article
CAS
PubMed
Google Scholar
Adkison JB, Khuntia D, Bentzen SM, Cannon GM, Tome WA, Jaradat H, Walker W, Traynor AM, Weigel T, Mehta MP. Dose escalated, hypofractionated radiotherapy using helical tomotherapy for inoperable non-small cell lung cancer: Preliminary results of a risk-stratified phase i dose escalation study. Technol Cancer Res Treat. 2008; 7(6):441–7. https://doi.org/10.1177/153303460800700605.
Article
CAS
PubMed
Google Scholar
Atzori F, Tabernero J, Cervantes A, Prudkin L, Andreu J, Rodriguez-Braun E, Domingo A, Guijarro J, Gamez C, Rodon J, Cosimo SD, Brown H, Clark J, Hardwick JS, Beckman RA, Hanley WD, Hsu K, Calvo E, Rosello S, Langdon RB, Baselga J. A phase i pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumors. Clin Cancer Res. 2011; 17(19):6304–12. https://doi.org/10.1158/1078-0432.ccr-10-3336.
Article
CAS
PubMed
Google Scholar
Berenson JR, Yellin O, Patel R, Duvivier H, Nassir Y, Mapes R, Abaya CD, Swift RA. A phase i study of samarium lexidronam/bortezomib combination therapy for the treatment of relapsed or refractory multiple myeloma. Clin Cancer Res. 2009; 15(3):1069–75. https://doi.org/10.1158/1078-0432.ccr-08-1261.
Article
CAS
PubMed
Google Scholar
Conroy T, Viret F, François E, Seitz JF, Boige V, Ducreux M, Ychou M, Metges JP, Giovannini M, Yataghene Y, Peiffert D. Phase i trial of oxaliplatin with fluorouracil, folinic acid and concurrent radiotherapy for oesophageal cancer. Br J Cancer. 2008; 99(9):1395–401. https://doi.org/10.1038/sj.bjc.6604708.
Article
CAS
PubMed
PubMed Central
Google Scholar
Day FL, Leong T, Ngan S, Thomas R, Jefford M, Zalcberg JR, Rischin D, McKendick J, Milner AD, Iulio JD, Matera A, Michael M. Phase i trial of docetaxel, cisplatin and concurrent radical radiotherapy in locally advanced oesophageal cancer. Br J Cancer. 2010; 104(2):265–71. https://doi.org/10.1038/sj.bjc.6606051.
Article
PubMed
PubMed Central
CAS
Google Scholar
Dong M, Ning Z-Q, Xing P-Y, Xu J-L, Cao H-X, Dou G-F, Meng Z-Y, Shi Y-K, Lu X-P, Feng F-Y. Phase i study of chidamide (CS055/HBI-8000), a new histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas. Cancer Chemother Pharmacol. 2012; 69(6):1413–22. https://doi.org/10.1007/s00280-012-1847-5.
Article
CAS
PubMed
Google Scholar
Forsyth P, Roldán G, George D, Wallace C, Palmer CA, Morris D, Cairncross G, Matthews MV, Markert J, Gillespie Y, Coffey M, Thompson B, Hamilton M. A phase i trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas. Mol Ther. 2008; 16(3):627–32. https://doi.org/10.1038/sj.mt.6300403.
Article
CAS
PubMed
Google Scholar
Frost A, Mross K, Steinbild S, Hedbom S, Unger C, Kaiser R, Trommeshauser D, Munzert G. Phase i study of the plk1 inhibitor BI 2536 administered intravenously on three consecutive days in advanced solid tumours. Curr Oncol. 2012; 19(1). https://doi.org/10.3747/co.19.866.
Gojo I, Tan M, Fang H-B, Sadowska M, Lapidus R, Baer MR, Carrier F, Beumer JH, Anyang BN, Srivastava RK, et al. Translational phase i trial of vorinostat (suberoylanilide hydroxamic acid) combined with cytarabine and etoposide in patients with relapsed, refractory, or high-risk acute myeloid leukemia. Clin Cancer Res. 2013; 19(7):1838–51.
Article
CAS
PubMed
PubMed Central
Google Scholar
Kantarjian HM, Padmanabhan S, Stock W, Tallman MS, Curt GA, Li J, Osmukhina A, Wu K, Huszar D, Borthukar G, Faderl S, Garcia-Manero G, Kadia T, Sankhala K, Odenike O, Altman JK, Minden M. Phase i/II multicenter study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD4877 in patients with refractory acute myeloid leukemia. Investig New Drugs. 2011; 30(3):1107–15. https://doi.org/10.1007/s10637-011-9660-2.
Article
CAS
Google Scholar
Kim KB, Hwu W-J, Papadopoulos NE, Bedikian AY, Camacho LH, Ng C, Hernandez IM, Frost AM, Jack MA, Hwu P. Phase i study of the combination of docetaxel, temozolomide and cisplatin in patients with metastatic melanoma. Cancer Chemother Pharmacol. 2008; 64(1):161–7. https://doi.org/10.1007/s00280-008-0861-0.
Article
PubMed
CAS
Google Scholar
Kimball KJ, Preuss MA, Barnes MN, Wang M, Siegal GP, Wan W, Kuo H, Saddekni S, Stockard CR, Grizzle WE, Harris RD, Aurigemma R, Curiel DT, Alvarez RD. A phase i study of a tropism-modified conditionally replicative adenovirus for recurrent malignant gynecologic diseases. Clin Cancer Res. 2010; 16(21):5277–87. https://doi.org/10.1158/1078-0432.ccr-10-0791.
Article
CAS
PubMed
PubMed Central
Google Scholar
Kunz PL, He AR, Colevas AD, Pishvaian MJ, Hwang JJ, Clemens PL, Messina M, Kaleta R, Abrahao F, Sikic BI, Marshall JL. Phase i trial of ixabepilone administered as three oral doses each separated by 6 hours every 3 weeks in patients with advanced solid tumors. Investig New Drugs. 2012; 30(6):2364–70. https://doi.org/10.1007/s10637-012-9800-3.
Article
CAS
Google Scholar
Lee K-W, Park SR, Oh D-Y, Park Y-I, Khosravan R, Lin X, Lee S-Y, Roh E-J, Valota O, Lechuga MJ, Bang Y-J. Phase i study of sunitinib plus capecitabine/cisplatin or capecitabine/oxaliplatin in advanced gastric cancer. Investig New Drugs. 2013; 31(6):1547–58. https://doi.org/10.1007/s10637-013-0032-y.
Article
CAS
Google Scholar
LoRusso P, Venkatakrishnan K, Chiorean EG, Noe D, Wu J-T, Sankoh S, Corvez M, Sausville EA. Phase 1 dose-escalation, pharmacokinetic, and cerebrospinal fluid distribution study of TAK-285, an investigational inhibitor of EGFR and HER2. Investig New Drugs. 2013; 32(1):160–70. https://doi.org/10.1007/s10637-013-9988-x.
Article
CAS
Google Scholar
Luke JJ, D’Adamo DR, Dickson MA, Keohan ML, Carvajal RD, Maki RG, de Stanchina E, Musi E, Singer S, Schwartz GK. The cyclin-dependent kinase inhibitor flavopiridol potentiates doxorubicin efficacy in advanced sarcomas: Preclinical investigations and results of a phase i dose-escalation clinical trial. Clin Cancer Res. 2012; 18(9):2638–47. https://doi.org/10.1158/1078-0432.ccr-11-3203.
Article
CAS
PubMed
PubMed Central
Google Scholar
Michaelson MD, Zhu AX, Ryan DP, McDermott DF, Shapiro GI, Tye L, Chen I, Stephenson P, Patyna S, Ruiz-Garcia A, Schwarzberg AB. Sunitinib in combination with gemcitabine for advanced solid tumours: a phase i dose-finding study. Br J Cancer. 2013; 108(7):1393–401. https://doi.org/10.1038/bjc.2013.96.
Article
CAS
PubMed
PubMed Central
Google Scholar
Mita M, Kelly KR, Mita A, Ricart AD, Romero O, Tolcher A, Hook L, Okereke C, Krivelevich I, Rossignol DP, Giles FJ, Rowinsky EK, Takimoto C. Phase i study of e7820, an oral inhibitor of integrin -2 expression with antiangiogenic properties, in patients with advanced malignancies. Clin Cancer Res. 2011; 17(1):193–200. https://doi.org/10.1158/1078-0432.ccr-10-0010.
Article
CAS
PubMed
Google Scholar
Oki Y, Buglio D, Fanale M, Fayad L, Copeland A, Romaguera J, Kwak LW, Pro B, de Castro Faria S, Neelapu S, Fowler N, Hagemeister F, Zhang J, Zhou S, Feng L, Younes A. Phase i study of panobinostat plus everolimus in patients with relapsed or refractory lymphoma. Clin Cancer Res. 2013; 19(24):6882–90. https://doi.org/10.1158/1078-0432.ccr-13-1906.
Article
CAS
PubMed
PubMed Central
Google Scholar
Pollyea DA, Kohrt HE, Gallegos L, Figueroa ME, Abdel-Wahab O, Zhang B, Bhattacharya S, Zehnder J, Liedtke M, Gotlib JR, Coutre S, Berube C, Melnick A, Levine R, Mitchell BS, Medeiros BC. Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia. Leukemia. 2011; 26(5):893–901. https://doi.org/10.1038/leu.2011.294.
Article
PubMed
CAS
Google Scholar
Rao AV, Rizzieri DA, DeCastro CM, Diehl LF, Lagoo AS, Moore JO, Gockerman JP. Phase i study of dose dense induction and consolidation with gemtuzumab ozogamicin and high dose cytarabine in older adults with AML. J Geriatr Oncol. 2012; 3(3):220–7. https://doi.org/10.1016/j.jgo.2012.02.002.
Article
Google Scholar
Sanborn SL, Cooney MM, Dowlati A, Brell JM, Krishnamurthi S, Gibbons J, Bokar JA, Nock C, Ness A, Remick SC. Phase i trial of docetaxel and thalidomide: a regimen based on metronomic therapeutic principles. Investig New Drugs. 2008; 26(4):355–62. https://doi.org/10.1007/s10637-008-9137-0.
Article
CAS
Google Scholar
Shapiro GI, McCallum S, Adams LM, Sherman L, Weller S, Swann S, Keer H, Miles D, Müller T, LoRusso P. A phase 1 dose-escalation study of the safety and pharmacokinetics of once-daily oral foretinib, a multi-kinase inhibitor, in patients with solid tumors. Investig New Drugs. 2012; 31(3):742–50. https://doi.org/10.1007/s10637-012-9881-z.
Article
CAS
Google Scholar
Srivastava S, Jones D, Wood LL, Schwartz JE, Nelson RP, Abonour R, Secrest A, Cox E, Baute J, Sullivan C, Kane K, Robertson MJ, Farag SS. A phase i trial of high-dose clofarabine, etoposide, and cyclophosphamide and autologous peripheral blood stem cell transplantation in patients with primary refractory and relapsed and refractory non-hodgkin lymphoma. Biol Blood Marrow Transpl. 2011; 17(7):987–94. https://doi.org/10.1016/j.bbmt.2010.10.016.
Article
CAS
Google Scholar
Tsimberidou AM, Camacho LH, Verstovsek S, Ng C, Hong DS, Uehara CK, Gutierrez C, Daring S, Stevens J, Komarnitsky PB, Schwartz B, Kurzrock R. A phase i clinical trial of darinaparsin in patients with refractory solid tumors. Clin Cancer Res. 2009; 15(14):4769–76. https://doi.org/10.1158/1078-0432.ccr-08-2984.
Article
CAS
PubMed
Google Scholar
Yamamoto K, Kokawa K, Umesaki N, Nishimura R, Hasegawa K, Konishi I, Saji F, Nishida M, Noguchi H, Takizawa K. Phase i study of combination chemotherapy with irinotecan hydrochloride and nedaplatin for cervical squamous cell carcinoma: Japanese gynecologic oncology group study. Oncol Rep. 2009; 21(4):1005–9.
Article
CAS
PubMed
Google Scholar
Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, Forero-Torres A. Brentuximab vedotin (sgn-35) for relapsed cd30-positive lymphomas. New Engl J Med. 2010; 363(19):1812–21.
Article
CAS
PubMed
Google Scholar
Garcia JA, Mekhail T, Elson P, Wood L, Bukowski RM, Dreicer R, Rini BI. Phase i/II trial of subcutaneous interleukin-2, granulocyte-macrophage colony-stimulating factor and interferon-alpha in patients with metastatic renal cell carcinoma. BJU Int. 2011; 109(1):63–69. https://doi.org/10.1111/j.1464-410x.2010.10011.x.
Article
PubMed
CAS
Google Scholar
Saraiya B, Gounder M, Dutta J, Saleem A, Collazo C, Zimmerman L, Nazar A, Gharibo M, Schaar D, Lin Y, Shih W, Aisner J, Strair RK, Rubin EH. Sequential topoisomerase targeting and analysis of mechanisms of resistance to topotecan in patients with acute myelogenous leukemia. Anti-Cancer Drugs. 2008; 19(4):411–20. https://doi.org/10.1097/cad.0b013e3282f5218b.
Article
CAS
PubMed
Google Scholar
Spunt SL, Grupp SA, Vik TA, Santana VM, Greenblatt DJ, Clancy J, Berkenblit A, Krygowski M, Ananthakrishnan R, Boni JP, Gilbertson RJ. Phase i study of temsirolimus in pediatric patients with recurrent/refractory solid tumors. J Clin Oncol. 2011; 29(21):2933–40. https://doi.org/10.1200/jco.2010.33.4649.
Article
CAS
PubMed
PubMed Central
Google Scholar
Yu KH, Yu SCH, Hui EP, Kam MKM, Vlantis AC, Yuen E, Chan ATC. Accelerated fractionation radiotherapy and late intensification with 2 intra-arterial cisplatin infusions for locally advanced head and neck squamous cell carcinoma. Head Neck. 2009. https://doi.org/10.1002/hed.21279.
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 2009; 45(2):228–47. https://doi.org/10.1016/j.ejca.2008.10.026. Publisher: Elsevier Ltd ISBN: 1879-0852 (Electronic).
Article
CAS
PubMed
Google Scholar
Cheson BD, Bennett JM, Kopecky KJ, Büchner T, Willman CL, Estey EH, Schiffer CA, Doehner H, Tallman MS, Lister TA, Lo-Coco F, Willemze R, Biondi A, Hiddemann W, Larson RA, Löwenberg B, Sanz MA, Head DR, Ohno R, Bloomfield CD, LoCocco F, International Working Group for Diagnosis StandardizationofResponseCriteria Treatment Outcomes. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol Off J Am Soc Clin Oncol. 2003; 21(24):4642–9. https://doi.org/10.1200/JCO.2003.04.036.
Article
Google Scholar
Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, Hillmen P, Keating M, Montserrat E, Chiorazzi N, Stilgenbauer S, Rai KR, Byrd JC, Eichhorst B, O’Brien S, Robak T, Seymour JF, Kipps TJ. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018; 131(25):2745–60. https://doi.org/10.1182/blood-2017-09-806398.
Article
CAS
PubMed
Google Scholar
Brock K, Homer V, Soul G, Potter C, Chiuzan C, Lee S. Dose-level toxicity and efficacy outcomes from dose-finding clinical trials in oncology. 2019. https://doi.org/10.25500/edata.bham.00000337.
Macdougall J. Analysis of Dose–Response Studies–Emax Model. In: Dose Finding in Drug Development. New York: Springer: 2006.
Google Scholar
Bornkamp B. DoseFinding: Planning and Analyzing Dose Finding Experiments. 2019. R package version 0.9-17. https://CRAN.R-project.org/package=DoseFinding. Accessed 14 Dec 2020.
Bürkner P-C. Advanced Bayesian multilevel modeling with the R package brms. The R Journal. 2018; 10(1):395–411. https://doi.org/10.32614/RJ-2018-017.
Article
Google Scholar
R Core Team R. A Language and Environment for Statistical Computing. Vienna: R Foundation for Statistical Computing; 2020. R Foundation for Statistical Computing. https://www.R-project.org/. Accessed 14 Dec 2020.
Google Scholar
Wickham H, Averick M, Bryan J, Chang W, McGowan LD, François R, Grolemund G, Hayes A, Henry L, Hester J, Kuhn M, Pedersen TL, Miller E, Bache SM, Mus̈ller K, Ooms J, Robinson D, Seidel DP, Spinu V, Takahashi K, Vaughan D, Wilke C, Woo K, Yutani H. Welcome to the tidyverse. J Open Source Softw. 2019; 4(43):1686. https://doi.org/10.21105/joss.01686.
Article
Google Scholar
Kay M. tidybayes: Tidy Data and Geoms for Bayesian Models. 2020. https://doi.org/10.5281/zenodo.1308151. R package version 2.0.3. http://mjskay.github.io/tidybayes/. Accessed 14 Dec 2020.
Wickham H. Ggplot2: Elegant Graphics for Data Analysis: Springer; 2016. https://ggplot2.tidyverse.org. Accessed 14 Dec 2020.
Lee SM, Backenroth D, Cheung YKK, Hershman DL, Vulih D, Anderson B, Ivy P, Minasian L. Case example of dose optimization using data from bortezomib dose-finding clinical trials. J Clin Oncol. 2016; 34(12):1395.
Article
CAS
PubMed
PubMed Central
Google Scholar
Zohar S, Baldi I, Forni G, Merletti F, Masucci G, Gregori D. Planning a bayesian early-phase phase i/ii study for human vaccines in her2 carcinomas. Pharm Stat. 2011; 10(3):218–26.
Article
PubMed
Google Scholar
Hazim A, Mills G, Prasad V, Haslam A, Chen EY. Relationship Between Response and Dose in Published, Contemporary Phase I Oncology Trials. J Natl Compr Cancer Netw JNCCN. 2020; 18(4):428–33. https://doi.org/10.6004/jnccn.2019.7375.
Article
Google Scholar
Yuan Y, Nguyen HQ, Thall PF. Bayesian Designs for Phase I-II Clinical Trials. Boca Raton: CRC Press; 2017.
Book
Google Scholar
Yuan Y, Yin G. Journal of the Royal Statistical Society: Series C (Applied Statistics). 2009; 58(5):719–736.
Zhang Y, Cao S, Zhang C, Jin IH, Zang Y. A bayesian adaptive phase i/ii clinical trial design with late-onset competing risk outcomes. Biometrics. 2020. https://doi.org/10.1111/biom.13347.
Sydes MR, Parmar MK, James ND, Clarke NW, Dearnaley DP, Mason MD, Morgan RC, Sanders K, Royston P. Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the mrc stampede trial. Trials. 2009; 10(1):1–16.
Article
CAS
Google Scholar
Chapple AG, Thall PF. A hybrid phase i-ii/iii clinical trial design allowing dose re-optimization in phase iii. Biometrics. 2019; 75(2):371–81.
Article
CAS
PubMed
PubMed Central
Google Scholar